Transformational year with acquisitions of Hexal and Eon Labs to make Sandoz a world leader in generics. Income advances 12% as margin improves 0.7 percentage points to 29.7% of net sales. Net sales rise 10% (+9% lc) based on excellent performances from strategic products.
Novartis continues to outpace competitors, gaining market share. Group net sales up 14% (+13% in local currencies) and operating income advancesġ0% as strong performances in all divisions are partially offset by acquisition-related costs. Record results with double-digit net sales and operating income growth in 2005. Pay-out ratio based on outstanding shares (%) Research and development as % of net sales (in USD millions unless indicated otherwise) Novartis Group Consolidated Financial Statements Want to discover, develop and successfully market innovative products to cure diseases, to ease suffering and to enhance the quality of life.Īlso want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.Ĭommitment to Health, Safety and Environment Rule 12g3-2(b) under the Securities Exchange Act of 1934. Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Report on Form 6-K dated February 8, 2006īy check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: QuickLinks - Click here to rapidly navigate through this document
0 kommentar(er)
